BioNano Genomics, Inc. (BNGO) Q3 Revs Miss Views

BioNano Genomics, Inc. (NASDAQ: BNGO) reported Q3 revenue of $3.3 million versus the consensus estimate of $4.44 million.

“Data continue to confirm and validate Saphyr’s potential to replace traditional cytogenetics methods for the detection of structural variants in certain blood cancers, and we are humbled to have globally recognized leaders in their field support the use of Saphyr over traditional methods,” said Erik Holmlin, Ph.D., CEO of Bionano. “We are now seeing Saphyr being accepted and recognized by world-class institutions and expect to see that trend continue. With our recent public offering, we believe we are well-positioned for continued growth.”

For earnings history and earnings-related data on BioNano Genomics, Inc. (BNGO) click here.

You May Also Be Interested In

• Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
• bioAffinity (BIAF) Tops Q2 EPS by 146c
• Atlassian results seen as 'game changer' for AI kills software worries